Richard Cathomas
Overview
Explore the profile of Richard Cathomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
3685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Condoluci A, Romano I, Dietrich D, Pini K, Stussi G, Muller G, et al.
Blood
. 2025 Feb;
PMID: 40009495
The rationale for combining ibrutinib and venetoclax (IV) in chronic lymphocytic leukemia (CLL) treatment lies in their complementary mechanisms of action. Studies investigating IV typically begin with a short initial...
2.
Goede J, Baumann C, Cathomas R, Khanna N, Lambert J, Lehmann T, et al.
Swiss Med Wkly
. 2024 Oct;
154:3559.
PMID: 39462479
Immunoglobulins for intravenous use (IVIgs) and subcutaneous use (SCIgs) can prevent recurrent and severe infections in patients with secondary antibody deficiencies that are frequently linked to haematological/oncological malignancies as well...
3.
Fischer S, Gillessen S, Stalder O, Terbuch A, Cathomas R, Schmid F, et al.
Eur Urol Open Sci
. 2024 Sep;
68:68-74.
PMID: 39308640
Background And Objective: Follow-up for patients with testicular cancer should ensure early detection of relapses. Optimal schedules and minimum requirements for cross-sectional imaging are not clearly defined, and guideline recommendations...
4.
Kaufmann E, Aeppli S, Arnold W, Balermpas P, Beyer J, Bieri U, et al.
World J Urol
. 2024 Sep;
42(1):527.
PMID: 39297968
Purpose: Optimal follow-up strategies following trimodal treatment for muscle invasive bladder cancer play a crucial role in detecting and managing relapse and side-effects. This article provides a comprehensive summary of...
5.
El Saadany T, Lorch A, Milowsky M, Vogl U, Cathomas R
Front Oncol
. 2024 Sep;
14:1427452.
PMID: 39281379
Immunotherapy with checkpoint inhibitors including atezolizumab, pembrolizumab and nivolumab has become an essential pillar in the management of muscle invasive and metastatic urothelial carcinoma. The field has evolved quickly in...
6.
Fankhauser C, Wettstein M, Christiansen A, Rothermundt C, Cathomas R, Kaufmann E, et al.
Urol Oncol
. 2024 Sep;
42(12):455.e9-455.e13.
PMID: 39261117
Purpose: MiR-371a-3p represents a novel liquid biomarker that detects all histologies of germ-cell tumors (GCT) except teratoma. However, it is currently unclear whether miR-371a-3p results obtained directly from RT-PCR (raw...
7.
Johnson K, Stoffel B, Schwitter M, Hayoz S, Mora A, Maranta A, et al.
Support Care Cancer
. 2024 Jul;
32(8):554.
PMID: 39066890
Purpose: Common side effects of taxane chemotherapy are nail toxicity and peripheral neuropathy (CIPN) causing severe impact on the quality of life. Different methods of cryotherapy to prevent these side...
8.
Fankhauser C, Cathomas R, Gillessen S, Rothermundt C
Eur Urol
. 2024 May;
86(5):477-478.
PMID: 38735820
No abstract available.
9.
Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabro F, Cathomas R, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672547
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to...
10.
Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser C, et al.
Prostate Cancer Prostatic Dis
. 2024 Apr;
27(3):422-431.
PMID: 38589645
Introduction: Enzalutamide, a second-generation androgen receptor inhibitor, is indicated for the treatment of metastatic disease, as well as in the treatment of non-metastatic castration resistant prostate cancer (PCa). This systematic...